Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo

Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2351-8. doi: 10.1161/01.atv.20.11.2351.

Abstract

We have previously shown that long-term treatment with an inflammatory cytokine from the adventitia causes the development of coronary vascular lesions, with the accumulation of macrophages. Recent studies in vitro have suggested that small G-protein Rho and its effector, Rho-kinase/ROK/ROCK, may be the key molecules for various cellular functions, including cell adhesion and movement. In this study, we examined whether adventitia-derived macrophages cause the formation of coronary vascular lesions in vivo and, if so, whether Rho-kinase is involved in the process. Porcine coronary segments from the adventitia were chronically treated with monocyte chemoattractant protein-1 alone, oxidized low density lipoprotein alone, or both. Vascular lesion formation (neointimal formation and development of vascular remodeling) was mostly enhanced at the coronary segment cotreated with monocyte chemoattractant protein-1 and oxidized low density lipoprotein, where the phosphorylation of myosin binding subunit of myosin phosphatase was increased, indicating an increased activity of Rho-kinase in vivo. Histological examination demonstrated that macrophages were accumulated at the adventitia and thereafter migrated into the vascular wall. Long-term oral treatment with fasudil, which is metabolized to a specific Rho-kinase inhibitor (hydroxyfasudil) after oral absorption, markedly inhibited the myosin binding subunit phosphorylation, the macrophage accumulation and migration, and the coronary lesion formation in vivo. These results indicate that Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in our porcine model in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / administration & dosage
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • Administration, Oral
  • Animals
  • Cell Movement / drug effects
  • Cell Movement / immunology
  • Coronary Vessels / drug effects
  • Coronary Vessels / enzymology*
  • Coronary Vessels / pathology*
  • Coronary Vessels / physiopathology
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / administration & dosage
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Macrophages / drug effects
  • Macrophages / enzymology*
  • Macrophages / pathology*
  • Male
  • Neovascularization, Pathologic / enzymology
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / pathology
  • Neovascularization, Pathologic / prevention & control
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / metabolism
  • Protein Serine-Threonine Kinases / physiology*
  • Swine
  • rho-Associated Kinases

Substances

  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Protein Serine-Threonine Kinases
  • rho-Associated Kinases
  • fasudil